Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease

(2019) Yoshimasa Aso et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients

(2019) Aino Latva-Rasku et al.   DIABETES CARE

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats

(2018) Krit Jaikumkao et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes

(2018) Seigo Sugiyama et al.   Journal of Atherosclerosis and Thrombosis

Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease

(2018) Fabrice Bonnet et al.   DIABETES & METABOLISM

Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)

(2018) Yoshio Sumida et al.   HEPATOLOGY RESEARCH

Diabetes association with liver diseases: an overview for clinicians

(2018) Abd Elkhalek Hamed et al.   Endocrine Metabolic & Immune Disorders-Drug Targets

Managing diabetes and liver disease association

(2018) Abd Elkhalek Hamed et al.   Arab Journal of Gastroenterology

Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes

(2017) Takahiro Tosaki et al.   INTERNAL MEDICINE

The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice

(2017) Yusuke Nakatsu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

(2017) Sebastian Steven et al.   Redox Biology

Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials

(2016) Soichi Sakai et al.   CLINICAL THERAPEUTICS

Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus

(2016) Sachie Hirose et al.   INTERNAL MEDICINE

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes

(2016) Xin Liao et al.   Scientific Reports

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

(2016) Yasushi Honda et al.   PLoS One

Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover stu

(2015) R. Nishimura et al.   DIABETES OBESITY & METABOLISM

Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2015) Yutaka Seino et al.   ENDOCRINE JOURNAL

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

(2015) Shirong Qiang et al.   Diabetology & Metabolic Syndrome

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus

(2015) Yutaka Seino et al.   Journal of Diabetes Investigation

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study

(2014) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients

(2014) Yuya Seko et al.   HEPATOLOGY RESEARCH

Non-alcoholic fatty liver disease in diabetics - prevalence and predictive factors in a multiracial hospital clinic population in Malaysia

(2013) Wah-Kheong Chan et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus

(2011) Raktim Kumar Ghosh et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

(2010) Nathalie C. Leite et al.   LIVER INTERNATIONAL

Histological Course of Nonalcoholic Fatty Liver Disease in Japanese Patients: Tight glycemic control, rather than weight reduction, ameliorates liver fibrosis

(2009) E. Hamaguchi et al.   DIABETES CARE